FEATURED CONTENT

• TrialScope EXTRA Keynotes Address Data Ownership, Health Communication

  Can your regulatory and protocol strategies keep pace with evolving data ownership, disclosure, and AI requirements? Explore key compliance risks, protections, and practical solutions.

• Piecing It All Together: Completing The Patient Recruitment Puzzle

  How can your recruitment strategy help sites reach qualified patients faster and improve enrollment performance?

• A Mission To Expand Recruitment Territory

  Learn how a proactive feasibility approach helps sponsors strengthen enrollment forecasting, mitigate risk, and implement timely interventions that improve study execution and clinical development.

• 2026 Annual Completed Clinical Trials Report: Strong Headwinds And Winds Of Change

  Are your Phase I–III/IV clinical studies prepared for today's regulatory landscape? Learn how leading organizations are addressing compliance, transparency, and data ownership risks.

• FDA Nudges Sponsors To Disclose Clinical Trial Results

  In March, the US FDA sent thousands of reminders to submit clinical trial results to ClinicalTrials.gov or complete the federal-mandated National Library of Medicine quality control review process.

• Ways To Avoid Rescue Trials From The Start

  What pushes a study into rescue mode? Explore the common causes of trial delays and how to address them before they impact timelines and outcomes.

• A Guide To Patient Engagement And Recruitment Solutions

  In this text we explore strategic solutions to patient recruitment and engagement challenges, emphasizing the importance of comprehensive patient engagement and recruitment strategies.

• Improving Rare Disease Recruitment With Data And AI

  Finding patients for rare disease clinical trials can be an uphill battle; fortunately, there are ways sponsors can address the most common stumbling blocks in the recruitment process.

• Trial Rescue And Reconnaissance

  Explore a strategic partnership that resulted in a rescue plan for a Phase III oncology trial that was facing high site decline rates.

• Pharma R&D Annual Review Supplement: New Active Substances

  Last year was by some distance the best year ever in terms of new active substances. Explore the 105 new debuts that easily outstrips that of the previous record holder, 2021’s, 97.

• Sol-Gel Builds Awareness Of Rare Skin Condition, Generates Leads

  Explore a 60-day HCP Awareness email campaign that surpassed industry benchmarks and generated a substantial number of leads.

• Sneak Peek Of Pharma R&D Annual Review

  Drug development experts remain intent on pharma’s prospects, especially in China, which have overtaken the US in first-time new drugs and continues to nurture a robust pipeline.

• Best Practices In Rare Disease Patient Recruitment

  Recruiting for rare disease clinical trials is daunting, and making patients aware of clinical trials, involving them in trial design, and building trust are a few ways sponsors can boost recruitment.

• SCOPE 2026 In The Rear-View Mirror

  Another SCOPE Summit is in the record books, and it was jam-packed with informative sessions. Themes included patient-centricity, AI (no surprise here), patient recruitment, and much more.

• Biopharma Reaping Numerous Benefits From AI

  Multiple AI use cases with significant impact have been identified, and they are expected to drive innovations in clinical trials, precision medicine, and commercial operations.

• Streamlining The Clinical Trial Workflow From Protocol Design To Regulatory Submission

  Learn how to create a direct line from clinical planning and protocol design to clinical trial disclosure to optimize efficiency across the entire trial lifecycle.

• Changing The Clinical Feasibility Game With AI

  AI is only as good as the data it’s built upon. Our customized AI platforms are constructed on a foundation of trustworthy, carefully curated data to produce detailed, expert-driven responses.

• Predictions For 2026 In Life Sciences

  Experts predict 2026 trends: more pragmatic trial design, expanded use of data and AI for patient matching, and registration and reporting of results for all human trials.

• Decision-Ready Data Restores Clinical Teams' Confidence

  The data underlying strategic decisions made by clinical teams often remain fragmented, backward-looking, or insufficiently validated. These teams need decision-ready data that brings clarity where it matters most.

• No More Swiss Holes: Filling The Gaps In Clinical Trial Disclosure

  This use case shows how sponsors can gain clarity on disclosure requirements when entering a new country.